HealthQuill UK
Merck & Co. will acquire UK-based Verona Pharma Plc for about $10 billion to gain access to a respiratory drug approved by the US regulator, according to a statement from Merck.
Drugs Health Pharma

Merck to acquire Verona Pharma for $10 billion to net respiratory drugĀ 

HQ Team July 9, 2025: Merck & Co. will acquire UK-based Verona Pharma Plc for about $10 billion and gain access to a.

Read More
The UK and Wellcome Trust will invest Ā£600 million to create a new health data research service to accelerate the discovery of life-saving drugs, improve patient care and make Britain ā€œthe best place in the worldā€ for medical research.
Drugs Health Pharma

UK, Wellcome to build Ā£600m health data service, fast-pace clinical trials

HQ Team May 19, 2025: The UK and Wellcome Trust will invest Ā£600 million to create a new health data research service to.

Read More
Britainā€™s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new under-the-skin injection version of the cancer therapy, nivolumab (Opdivo), offering a quicker administration option for eligible patients than the currently available drip treatment.Ā 
Drugs Medical Pharma

UK regulator clears subcutaneous injection of Bristol Myers for cancers

HQ Team May 1, 2025: Britainā€™s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new under-the-skin injection version of the cancer.

Read More
Kingā€™s and University College of London researchers have developed an artificial intelligence tool that can detect 64% of brain abnormalities, that radiologists miss, in epileptic child patients.
Health Medical Research

UK researchers develop AI tool to detect brain lesions in epileptic children

Kingā€™s and University College of London researchers have developed an artificial intelligence tool that can detect 64% of brain abnormalities, that radiologists miss,.

Read More
FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing the Anglo-Swedish firm to gain access to an anaemia drug in the worldā€™s most populated nation.
Drugs Health Pharma

AstraZeneca Plc buys China unit of FibroGen Inc for $160 million

HQ Team February 21, 2025: FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing.

Read More
Researchers at Cambridge are developing implants that could help repair damaged brain cells and treat diseases like Parkinsonā€™s.
Drugs Health Research

Cambridge researchers making brain implants to treat Parkinsonā€™s

Researchers at Cambridge are developing implants that could help repair damaged brain cells and treat diseases like Parkinsonā€™s.

Read More
Britainā€™s National Health Service will provide a gene therapy that may cure sickle cell disease for patients 12 years and older, according to a National Institute for Health and Care Excellence (NICE) statement.
Drugs Health Medical

UKā€™s NHS to provide gene therapy that may cure sickle cellĀ  disease in adults

Britainā€™s National Health Service will provide a gene therapy that may cure sickle cell disease for patients 12 years and older, according to.

Read More
Britain has detected two cases of Clade Ib mpox, a variant, in household contacts of the first case, taking the total to three since last week, according to the UK Health Security Agency (UKSHA).
Drugs Health Pharma

Britain detects two more cases of mpox variant, risk ā€˜remains lowā€™

Britain has detected two cases of Clade Ib mpox, a variant, in household contacts of the first case, taking the total to three.

Read More
Indiaā€™s coronary drug-eluting stent market may grow at a compound annual growth rate of 4% until 2033 on the back of a rise in coronary artery diseases, according to UK-based data analytics and consulting company, GlobalData.
Drugs Medical Pharma

Coronary drug-eluting stent market to grow 4% in India till 2033: Report

Indiaā€™s coronary drug-eluting stent market may grow at a compound annual growth rate of 4% until 2033 on the back of a rise.

Read More
UK-based DIOSynVax, a biotechnology company,Ā has developed a single candidate vaccine neutralizing immune responses across the spectrum of very diverse H5 subtypes of influenza viruses.
Drugs Health Medical

UKā€™s DIOSynVax develops single candidate vaccine for bird fluĀ virus

UK-based DIOSynVax, a biotechnology company,Ā has developed a single candidate vaccine neutralizing immune responses across the spectrum of very diverse H5 subtypes of influenza.

Read More